Literature DB >> 7558806

Prognostic significance of prostaglandin E2 production in fresh tissues of head and neck cancer patients.

C H Snyderman1, M Milanovich, R L Wagner, J T Johnson.   

Abstract

BACKGROUND: Immunosuppressive prostaglandins may play a role in the biologic behavior of head and neck cancer. Increased levels of prostaglandin E2 (PGE2) have been measured in squamous cell carcinoma of the head and neck (SCCHN).
METHODS: To address this question, tissue levels of PGE2 were measured in tumor tissues, normal mucosa, and lymph nodes of 37 patients undergoing tumor resections. Tissue specimens were placed in culture media, and levels of PGE2 released into the supernatant were measured by radioimmunoassay.
RESULTS: Tissue levels of PGE2 were significantly greater in tumor and normal mucosal tissues compared to lymph nodes (p = 0.0003). There was no difference between metastatic and tumor-free lymph nodes. Although tumor tissue levels of PGE2 were not associated with tumor stage, increased levels of PGE2 were associated with increased 2-year disease-free survival (p = 0.02).
CONCLUSIONS: Although PGE2 may have adverse effects on local immune function in tumor tissues, improved survival of patients with increased local PGE2 production may be indicative of an enhanced immunologic response to the tumor which has a favorable impact on outcome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7558806     DOI: 10.1002/hed.2880170206

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  8 in total

1.  Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis.

Authors:  O Gallo; A Franchi; L Magnelli; I Sardi; A Vannacci; V Boddi; V Chiarugi; E Masini
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

Review 2.  Immunology and Immunotherapy of Head and Neck Cancer.

Authors:  Robert L Ferris
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

3.  Cyclooxygenase-2--An Imperative Prognostic Biomarker in Oral Squamous Cell Carcinoma--An Immunohistochemical Study.

Authors:  Aditi Amit Byatnal; Amit Byatnal; Subhalakshmi Sen; Vasudev Guddattu; Monica Charlotte Solomon
Journal:  Pathol Oncol Res       Date:  2015-05-13       Impact factor: 3.201

4.  A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation.

Authors:  Aline Correa Abrahao; Rogerio M Castilho; Cristiane H Squarize; Alfredo A Molinolo; Decio dos Santos-Pinto; J Silvio Gutkind
Journal:  Oral Oncol       Date:  2010-10-14       Impact factor: 5.337

5.  Decreased risk of squamous cell carcinoma of the head and neck in users of nonsteroidal anti-inflammatory drugs.

Authors:  Neda Ahmadi; Radoslav Goldman; Françoise Seillier-Moiseiwitsch; Anne-Michelle Noone; Ourania Kosti; Bruce J Davidson
Journal:  Int J Otolaryngol       Date:  2010-06-03

Review 6.  Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.

Authors:  Jonathan Moreira; Alexander Tobias; Michael P O'Brien; Mark Agulnik
Journal:  Drugs       Date:  2017-05       Impact factor: 11.431

7.  Expression of cyclooxygenase 2 in oral submucous fibrosis: An immunohistochemical pilot study.

Authors:  Shruthi Rangaswamy; Rajkumar Garudanahally Chikkalingaiah; P Sharada; Vinod K Kumar
Journal:  J Oral Maxillofac Pathol       Date:  2019 May-Aug

8.  MicroRNA-21 regulates prostaglandin E2 signaling pathway by targeting 15-hydroxyprostaglandin dehydrogenase in tongue squamous cell carcinoma.

Authors:  Qianting He; Zujian Chen; Qian Dong; Leitao Zhang; Dan Chen; Aditi Patel; Ajay Koya; Xianghong Luan; Robert J Cabay; Yang Dai; Anxun Wang; Xiaofeng Zhou
Journal:  BMC Cancer       Date:  2016-08-25       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.